Efforts to minimize human interaction and reduce the risk of COVID-19 infection are taking the shine off the most expensive seats onboard commercial aircraft.
Companies, workers and lawmakers in three countries have spent the past year in limbo awaiting final touches on the U.S.-Mexico-Canada free-trade agreement. Now they have a better sense of who won—and who lost.
The House’s move toward impeachment proceedings against President Trump changes the calculus in handicapping the trade war, whether prescription drug pricing gets addressed and any other regulatory issues.
President Donald Trump’s plan to import cheap Canadian drugs overlooks a crucial fact: Canada’s pharmaceutical supply chain is beholden to the drugmakers.
The two companies plan to build as many as 20 automated grocery warehouses in the United States to help Cincinnati-based Kroger—which has about 70 stores in central Indiana—turbocharge its e-commerce operation.
One thing’s for sure, for investors who had been almost completely starved of good news all month, Wednesday brought it coursing back in a flurry.
One of the toughest years for financial markets in half a century got appreciably worse Tuesday, with simmering weakness across assets boiling over to leave investors with virtually nowhere to hide.
There is growing concern among autonomous-vehicle backers that artificial intelligence capable of real-world driving is further away than many predicted just a few years ago.
Investors, for their part, sent a clear signal that they favor a Schnatter-less Papa John’s: Shares rose as much as 16 percent, the most in six years, on Thursday.
The new tax law will be anything but simple for many affluent Americans, who are now inundating their accountants for advice.
As NCAA committees meet next week to discuss which cities will host championships through 2022, the organization finds itself in the middle of a national discussion on civil rights that will test its ability to influence public policy and its commitment to its own stated values.
The rapid turnover is a symptom of the quickly changing retail industry, as shifting consumer behavior demands new strategies from companies trying to keep up.
President-elect Donald Trump is reviving the persuasive art of “jawboning” as he uses the bully pulpit to strong-arm straying manufacturers. But for how long will it be effective, and is it in the long-term best interest of the economy?
Pharma giant Novo Nordisk announced Thursday that it is cutting 1,000 jobs after slashing forecasts for 2016, citing lower prices for diabetes drugs. Novo and competitors such as Indianapolis-based Eli Lilly will likely have to keep tightening their belts as prices and profit margins fall, experts say.
The case for Mike Pence as running mate for Donald Trump is he’d bring credibility with evangelical Christians and Republican-elected officials across the ideological spectrum, constituencies with whom Trump’s reputation is shaky.
Shares in WP Glimcher Inc. fell nearly 7 percent Monday after the Columbus-based retail landlord refuted reports it was involved in merger negotiations with Indianapolis-based Kite Realty Group Trust.
Analysts have consistently given the Indianapolis-based company some of the lowest ratings among a group of 16 large drugmakers, but Lilly shares have been on a five-year rally.
Seeing mergers like Anthem’s planned acquisition of Cigna Corp., hospitals could decide that striking deals of their own could improve their negotiating power over medical reimbursements.